Innate Pharma S.A. (NASDAQ:IPHA) Q2 2023 Earnings Conference Call September 14, 2023 8:00 AM ET
Company Participants
Henry Wheeler - VP, IR & Communication
Mondher Mahjoubi - CEO
Joyson Karakunnel - Interim Chief Medical Officer
Yannis Morel - EVP, BD and Product Portfolio Strategy
Frederic Lombard - CFO
Conference Call Participants
Ashiq Mubarack - Citi
Jingming Chen - Evercore ISI
Daina Graybosch - Leerink Partners
Operator
Hello, and welcome to the Innate Pharma First Half 2023 Financial Results and Business Update Conference Call. I would like to advise all participants that this call is being recorded.
I'd now like to welcome Henry Wheeler to begin the conference. Henry, over to you.
Henry Wheeler
Welcome, everyone. This morning, Innate issued a press release providing a business update for our H1 2023 financial results and business update. We look forward to highlighting the progress made during the year to-date as well as addressing future goals and milestones. The press release and today's presentation are both available on the IR section of our website.
On Slide 2, before we start, I'd like to remind you that we will make forward-looking statements regarding the financial outlook in addition to regulatory and product plan development. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted.
On Slide 3, on today's call we will be joined by Mondher Mahjoubi, our Chief Executive Officer, who will then hand over to Joyson Karakunnel, Interim Chief Medical Officer, who will cover updates on lacutamab and monolizumab. Yannis Morel, EVP of BD and Product Portfolio Strategy will then discuss our ANKET and ADC platforms. And then we have our CFO, Frederic Lombard to cover the financials.
Mondher, I'll now hand over to you.
Mondher Mahjoubi
Thank you, Henry. Good morning, good afternoon, everyone.
Please move to Slide 4. Let me start by welcoming Dr. Sonia Quaratino to Innate Pharma as Chief Medical Officer, as we announced at this moment. We are looking forward to Sonia joining the team next month with her wealth of expertise in the field of oncology product development. Dr. Quaratino joins us at an exciting time of clinical momentum for Innate Pharma and we look forward to working together to advance Innate pipeline and you will have the opportunity to meet with Dr. Quaratino at our next quarterly earning calls.
I would, of course, like to extend a great thanks to Joyson for all his contribution over the last years, and wish him well in his next steps. Joyson will ensure a smooth transition period as Sonia comes on board.